DOCSLIB.ORG

COVID-19 Vaccines Update Supplement Week Of: 21Sth June, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Vaccines Update Supplement Week Of: 21Sth June, 2021 CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 21sth June, 2021 I. Overview of Development and Regulatory Approvals: • 102 candidate vaccines are in clinical development: 18 in Phase 3 trials, and 5 in Phase 4 trials – Table 1; Figure in COVID-19 Vaccines and Therapeutics Regulatory Tracker (Phases tab). • 18 vaccines have received regulatory approvals in various countries, and 18 are at various stages of engagement with WHO for emergency use listing (EUL) including vaccines made in Cuba. • 8 vaccines have been approved by WHO for EUL to date: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), Janssen-Cilag, AstraZeneca (Vaxzevria™), Moderna (mRNA-1273), Sinopharm-BIBP and Sinovac COVID-19 vaccine – CoronaVac: Table 4. • COVID-19 vaccine interim recommendations by the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) for reviewed vaccines may be found at: SAGE COVID-19 materials. • CARPHA’s COVID-19 vaccine regulatory tracker provides an overview of profiles and regulatory approvals for various candidate vaccines and therapeutics. This sheet includes information on the efficacy of the vaccines in light of current variants of concern, as per WHO updates. • CARPHA-CRS has recommended 7 COVID-19 vaccines to Member States to date – Table 4. The CRS has started its review of Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac. Table 1: Candidate Vaccines under Clinical evaluation, by type or platform. Platform Description Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 Phase 4 Total WHO EUL PS Protein subunit 8 11 5 2 6 0 32 0 VVnr Viral Vector (non- 7 4 0 1 2 2 16 4 replicating) DNA DNA 4 3 0 2 1 0 10 0 IV Inactivated Virus 4 2 1 1 7 1 16 2 RNA RNA 7 3 2 0 2 2 16 2 VVr Viral Vector 0 1 1 0 0 0 2 0 (replicating) VLP Virus Like Particle 2 2 0 1 0 0 5 0 VVr + APC VVr + Antigen 1 1 0 0 0 0 2 0 Presenting Cell LAV Live Attenuated 2 0 0 0 0 0 2 0 Virus VVnr + VVnr + Antigen 0 1 0 0 0 0 1 0 APC Presenting Cell Total 35 28 9 7 18 5 102 8 Source: World Health Organization. Draft landscape of COVID-19 candidate vaccines. WHO, Geneva, 18th June 2021. Available at: Draft landscape of COVID-19 candidate vaccines (who.int). 1: 21.june.2021 II. Vaccine Deployment in the Caribbean Several Caribbean countries have approved / received COVID-19 vaccines purchases and/or donations. ▪ 14 Caribbean countries have received vaccine deliveries from COVAX as of 21st June, 2021. ▪ Based on data collected by the Global Change Data Lab’s Our World in Data site, between 1.05% and 62% of populations in CARPHA Member States (where available) have been fully vaccinated against COVID-19 – both doses (Figure 1). Completed schedules per 100 persons, based on data from PAHO are shown in Figure 2. ▪ Based on the PAHO Dashboard of COVID-19 Vaccination in the Americas as of 18th June, 2021, among CARPHA Member States, vaccine administration (at least 1 dose) ranges from 6.5 to 137.4 doses per capita (Figure 3). Approximately 2,013,813 doses have been administered, with an average of 59.6 doses per capita among CMS – Table 3. FIGURE 1: Share of People vaccinated against COVID-19 in CARPHA Member States Source: https://ourworldindata.org/ 2: 21.june.2021 FIGURE 2: Completed Schedules of COVID-19 Vaccination per 100 persons, as of 18th June, 2021 (PAHO) Source: PAHO COVID-19 Vaccination in the Americas Dashboard. 3: 21.june.2021 FIGURE 3: COVID-19 Vaccine Doses Administered per 100 persons, as of 18th June, 2021 Table 2: COVID-19 Vaccines Deployed Among CARPHA Member States as of 18th June, 2021 Country ¥ Vaccine(s) Number of Doses Doses per 100 persons Anguilla AstraZeneca - Vaxzevria 15, 198 82.5 Antigua & Barbuda AstraZeneca – not specified 60, 011 60.8 Aruba Information not available 122, 680 114.4 Bahamas AstraZeneca – not specified 68, 119 17.2 Barbados AstraZeneca – not specified 153, 350 53.3 Bonaire Pfizer BioNTech - Comirnaty 26, 469 131.7 Belize AstraZeneca – not specified 95, 452 23.6 Bermuda Information not available 76, 526 106.3 Cayman Islands Pfizer BioNTech - Comirnaty 86, 711 137.4 Curacao Pfizer BioNTech - Comirnaty 163, 328 99.1 Dominica Beijing CNBG – Inactivated; AstraZeneca – not 52 38, 646 specified Grenada AstraZeneca – not specified 29, 157 25.8 Guyana Information not available 319, 096 40.4 Jamaica AstraZeneca – not specified 194, 315 6.5 Montserrat AstraZeneca - Vaxzevria 2, 600 48.1 Saba Information not available 1, 300 67.3 Sint Eustatius Information not available 2, 236 71.3 Sint Maarten Pfizer BioNTech - Comirnaty 36, 209 81.5 St. Kitts & Nevis AstraZeneca – not specified 32, 804 60.6 4: 21.june.2021 Country ¥ Vaccine(s) Number of Doses Doses per 100 persons St. Lucia AstraZeneca – not specified 50, 869 27.6 St. Vincent & Gamaleya - Sputnik V; AstraZeneca – not 20.7 22, 980 Grenadines specified Suriname AstraZeneca – not specified 161, 829 27.4 Trinidad & Tobago Beijing CNBG – Inactivated; AstraZeneca – not 13.9 195, 540 specified Turks and Caicos Pfizer BioNTech - Comirnaty 38, 110 66.8 Virgin Islands (British) AstraZeneca - Vaxzevria 20, 278 53.1 Source: PAHO COVID-19 Vaccination in the Americas Dashboard. ¥ No information on doses/100p found for Haiti. 5: 21.june.2021 Table 4: COVID-19 Vaccines with Regulatory Approvals by WHO EUL Consideration Vaccine WHO EUL status and Developers (Vaccine name) Dosing Storage ¥ Authorized by Platform anticipated decision date: WHO EUL status – Approved Recommended by CRS Pfizer-BioNTech mRNA 2 doses Ship: -80⁰C to -60⁰C; WHO EUL + CRS + 88 countries including United December 2020 (completed) (INN: tozinameran; BNT162b2 I.M. Store: -25°C to -15°C Kingdom, Canada, Mexico, USA, Chile, Argentina, / COMIRNATY) (2wk); 2⁰C to 8⁰C Switzerland, EU, Colombia, Israel, Australia, Brazil, (12h) Guyana, Cayman Islands, Aruba, Bermuda, Curacao, St Maarten, Turks/Caicos, Guyana, Suriname, St Vincent & Grenadines. AstraZeneca-Oxford + SK Recombinant 2 doses 2°C to 8°C (6 mo.) WHO EUL + South Korea via COVAX / PAHO Approved: 15th February Bioscience (supplier)* ChAdOx1-S I.M. (AZD1222) adenoviral vector Serum Institute of India + Recombinant 2 doses 2°C to 8°C (6 mo.) WHO EUL + CRS + 42 countries including India, Approved: 15th February AstraZeneca-Oxford ChAdOx1-S I.M. Argentina, Bangladesh, South Africa, Guyana, Canada University adenoviral (+VerityPharma), Brazil, OECS Member States, (AZD1222; Covishield) vector Barbados, Bahamas, Guyana, Trinidad & Tobago, Suriname, Jamaica, Antigua & Barbuda, Dominica, Grenada, St Kits & Nevis, St Lucia, St Vincent & Grenadines. Janssen-Cilag (Johnson & Viral vector 1 dose I.M. Sealed: 2-8°C or 9- WHO EUL + 49 countries including: USA, Canada, South Approved: 12th March; Johnson) (JNJ-78436735) (non-replicating) 25°C (12h); Open: 2- Africa, Bahrain, Colombia, via COVAX/ PAHO; African Aspen South Africa: May 2021 8°C (6h) or 25°C (2h). Medical Supplies Platform (AMSP), Mexico, St Vincent Other sites: Pending & Grenadines, MHRA, Swissmedic, Brazil, MPA, AEMPS. AstraZeneca-Oxford Recombinant 2 doses 2°C to 8°C (6 mo.) WHO EUL + CRS + 110 countries including UK, Approved: 16th April University (AZD1222) ChAdOx1-S I.M. Argentina, Mexico, Brazil, EU, Canada (AZ Canada), VAXZEVRIA™ adenoviral Colombia, Chile, Anguilla, BVI, Montserrat (UK node), vector Guyana; via COVAX/ PAHO Moderna & NIAID mNRA-based in 2 doses Ship: -25°C to -15°C; 53 countries including Canada, Switzerland, United Approved: 30th April (mRNA-1273) lipid I.M. Sealed: 2-8°C (30d) Kingdom, United States, EU, Guyana, St Vincent & INN: elasomeran nanoparticle or 9-25°C (12h); Grenadines. (LNP) Open: 2-25°C (6h) Sinopharm + China National Inactivated virus 2 doses 2°C to 8°C (24 mo.) 53 countries including China, Bahrain, United Arab Approved: 7th May Pharmaceutical Group + I.M. Emirates, Egypt, Jordan, Iraq, Pakistan, Serbia, Peru, Beijing Institute of Biological Argentina, Chile, Guyana, Trinidad & Tobago Products (BBIBP-CorV) 6: 21.june.2021 Vaccine WHO EUL status and Developers (Vaccine name) Dosing Storage ¥ Authorized by Platform anticipated decision date: Pending review by CRS Sinovac COVID-19 vaccine Inactivated virus 2 doses 2°C to 8°C 29 countries including China, Colombia, Turkey, Approved: 1st June (Vero Cell [Inactivated]) – I.M. Indonesia, Brazil, Chile, México, Guyana CoronaVac WHO EUL status – Pending/Not under review yet (Not eligible for CRS review) Gamaleya Research Institute Adenovirus Viral 2 doses 2°C to 8°C 68 countries including Russia, Argentina, Guinea, Anticipated date will be set & Russian Health Ministry vector (non- I.M. Bolivia, Venezuela, Paraguay, México, Belize, Guyana, St once all data is submitted and (Sputnik V) replicating) Vincent & Grenadines, Antigua & Barbuda follow-up of inspection observations completed. AstraZeneca-Oxford Recombinant 2 doses 2°C to 8°C WHO EUL + CRS + 110 countries including UK, Anticipated date will be set University [PMDA] ChAdOx1-S I.M. Argentina, Mexico, Brazil, EU, Canada (AZ Canada), once all information has been adenoviral Colombia, Chile, Anguilla, BVI, Montserrat (UK node), received. vector Guyana; via COVAX/ PAHO AstraZeneca-Oxford Recombinant 2 doses 2°C to 8°C WHO EUL + CRS + 110 countries including UK, Anticipated date will be set University [TAG] ChAdOx1-S I.M. Argentina, Mexico, Brazil, EU, Canada (AZ Canada), once all information has been adenoviral Colombia, Chile, Anguilla, BVI, Montserrat (UK node), received. vector Guyana; via COVAX/ PAHO CanSino Biological Inc + Adenovirus; 1 dose I.M. 2°C to 8°C 5 countries: China, Mexico, Pakistan, Hungary, Chile Rolling data review starting in Beijing Institute of Biological Viral vector June 2021 Products (non-replicating) (Convidicea (Ad5-nCoV)) NOVAVAX (NVX-CoV2373) Protein subunit 2 doses 2°C to 8°C None to date Pre-submission meeting held I.M.
Load more

Recommended publications
  • Cuba: One Year Into the Pandemic
    BULLETIN OF PAHO/WHO IN CUBA Vol. 25 No.1 JANUARY-MARCH 2021 CUBA: ONE YEAR INTO THE PANDEMIC 04 43 46 50 OUR NEWS: NOTEWORTHY: OVER A STORY A CUP OF TO TELL: Interview Benefits with Cuba's of a Cúrcumal onga COFFEE Dr. Ricardo Minister pdroject uring WITH… Pereda González: of Public Health, thep andemic Coordinator of Dr. José Angel Concepción the COVID-19 Clinical Portal Miranda Campa Experts Commission Huergo Pathways to Health is a bulletin prepared by the office of the Pan American Health Organization/World Health Organization EDITORIAL (PAHO/WHO) in Cuba. Its main aim is to share the most important aspects of the On March 11, 2020, the Director-General of the World Health Representation's technical cooperation with Organization (WHO) declared the novel coronavirus a pandemic, the country's Ministry of Public Health which at the time already affected 114 nations. Coincidentally, (MINSAP) and other institutions. that same day, the Pedro Kourí Tropical Medicine Institute (IPK) in Havana confirmed the first COVID-19 cases in Cuba. At the one-year anniversary of the pandemic in Cuba, this issue is dedicated to One year into the pandemic, more than 115 million cases and close to 2.6 million deaths have been reported from the disease systematically review key aspects of the worldwide. About half of both these cases and deaths have been national response over the last months. In registered in the Americas, with results differing according to how particular, it includes an interview with the well the response has been organized, how robust the healthcare Minister of Public Health, Dr.
    [Show full text]
  • Revision Rápida
    REVISION RÁPIDA EVALUACIÓN DE LAS CARACTERÍSTICAS DE ALMACENAMIENTO, TRANSPORTE Y DISTRIBUCIÓN DE LAS VACUNAS COVID-19 EN ESTUDIO, Y LAS CARACTERÍSTICAS CLÍNICAS DE LA POBLACIÓN CANDIDATA A VACUNACIÓN Noviembre de 2020 El Instituto de Evaluación Tecnológica en Salud – IETS, es una corporación sin ánimo de lucro, de participación mixta y de carácter privado, con patrimonio propio, creado según lo estipulado en la Ley 1438 de 2011. Su misión es contribuir al desarrollo de mejores políticas públicas y prácticas asistenciales en salud, mediante la producción de información basada en evidencia, a través de la evaluación de tecnologías en salud y guías de práctica clínica, con rigor técnico, independencia y participación. Sus miembros son el Ministerio de Salud y Protección Social – MinSalud, el Departamento Administrativo de Ciencia, Tecnología e Innovación – Colciencias, el Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA, el Instituto Nacional de Salud – INS, la Asociación Colombiana de Facultades de Medicina – ASCOFAME y la Asociación Colombiana de Sociedades Científicas – ACSC. Autores Lucas López Quiceno. Médico y cirujano, Especialista en Epidemiología, Magister en Epidemiología, Magíster en economía de la salud (c). Instituto de Evaluación Tecnológica en Salud - IETS. Jhyld Carolaind Camacho Barbosa, Nutricionista y Dietista, Magister en Epidemiología. Instituto de Evaluación Tecnológica en Salud - IETS. Kelly Estrada-Orozco. Médica, Magister en Epidemiología Clínica, Magister en Neurociencia. Doctorado en Salud Pública (actual). Doctorado en Epidemiología Clínica (actual). Instituto de Evaluación Tecnológica en Salud - IETS. Revisores Cortes-Muñoz, Ani Julieth. Bacterióloga y laboratorista clínica. MSc. Epidemiología. Instituto de Evaluación Tecnológica en salud - IETS. Ospina-Lizarazo, Nathalie. Nutricionista Dietista. MSc. Epidemiología Clínica. Instituto de Evaluación Tecnológica en salud - IETS.
    [Show full text]
  • Iran Hopes to Defeat COVID with Home-Grown Crop of Vaccines
    Q&A Iran hopes to defeat COVID with home-grown crop of vaccines Iran is one of few Middle Eastern nations to transfer money is restricted, it is difficult with the capacity to develop vaccines. It to buy drugs and medicines. And we have has been doing so in earnest: more than the technology to produce vaccines, so why ten are in development, but little is known not use it? To ensure the safety of Iranians, it about them outside Iran. Nature speaks makes sense to develop a variety of vaccines to Kayhan Azadmanesh, head of the using different research and development virology division at the Pasteur Institute of strategies, as China has done. Iran in Tehran, about the nation’s vaccine landscape. Azadmanesh also advises the Why are Iranian researchers reluctant to Iranian government and is developing publicize their work internationally? vaccines through his spin-off company This could be another effect of the sanctions. Humimmune Biotech. Researchers in Iran might not want to draw too much attention to their work in case they How badly has the pandemic affected Iran? put potential partnerships in jeopardy or they Since January 2020, we’ve had five waves. run the risk of losing access to raw materials. We’re currently experiencing the highest Researchers are also extremely busy number of new cases reported so far, with during the pandemic. But some have started MAJID ASGARIPOUR/WANA VIA REUTERS MAJID ASGARIPOUR/WANA around 40,000 a day, and the most common to share results. In June, the researchers variant we detect is Delta.
    [Show full text]
  • The Covid–19 Pandemic and Haemglobin Isorders
    THE COVID–19 PANDEMIC AND HAEMGLOBIN ISORDERS UPDATE: 29 June 2021 Vaccinations “Immunization is a key component of primary health care and an indisputable human right. It is also one of the best health investments money can buy. Vaccines are thus critical to the prevention and control of infectious-disease outbreaks. They underpin global health security and will be a vital tool in the battle against antimicrobial resistance”. – WHO https://www.who.int/health- topics/vaccines-and- immunization “Since the beginning of the pandemic, WHO has taken steps to prevent an “infodemic”— defined by the organization as “an overabundance of information and the rapid spread of misleading or fabricated news, images, and videos.” WHO and the Wikimedia Foundation, the nonprofit organization that administers Wikipedia, have established a collaboration to expand the public’s access to the latest and most reliable information about COVID-19”. Information about the initiative is available at: https://www.who.int/news/item/22-10- 2020- the-world-health-organization-and-wikimedia-foundation-expand-access-to- trusted- information-aboutcovid-19-on-wikipedia TIF shares the concerns of false information and misleading overabundance of information. This often happens in the effort to enhance hope to a population that is suffering not only from the disease itself, but also from its economic future, since lockdown/isolation practices are stifling the market economies of every country around the world. Hope however, must be based on realistic expectations and information. For these reasons, TIF updates on new developments concerning vaccinations and new therapies are scanned for accuracy and are reviewed now more regularly.
    [Show full text]
  • COVID-19 Vaccine Coverage Soumya Swaminathan, WHO Chief Scientist
    COVID-19 vaccine coverage Soumya Swaminathan, WHO Chief Scientist 6 July 2021 DATA AS OF 5 JULY 8:00 AM CET 3,197M doses of COVID-19 vaccine have been administered1 in 215 countries, areas, territories & economies2 Total doses administered per 100 population Doses administered per 100 population 0-5 6-20 21-50 50+ Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. 1 1. Source of data: WHO; Bloomberg; 2. Total of 220 countries, areas, territories & economies: 218 economies listed by World Bank + WHO Member states Cook Islands + Niue DATA AS OF 5 JULY 8:00 AM CET COVAX has now shipped 95.9M doses to 135 participants Incl. 69 LMIC/LICs; 40 participants started their first campaigns thanks to COVAX doses COVAX participants that received COVAX doses (incl. ones that started with others) Economies vaccinating only with bilateral doses or donations Economy not yet started vaccinating1 1. Burundi, Eritrea, United Republic of Tanzania, Haiti, Democratic People's Republic of Korea Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Status of COVID-19 Vaccines Within WHO EUL/PQ Evaluation Process
    Vaccines Guidance Document 07 April 2021 Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process Manufacturer Name of Vaccine NRA of Record Platform EOI Pre-submission Dossier accepted for Status of assessment** Anticipated decision accepted meeting held review* date*** 1. BNT162b2/COMIRNATY EMA Nucleoside modified mNRA Finalized 31/12/20 Tozinameran (INN) 2. AZD1222 Core – EMA Non- Recombinant ChAdOx1 adenoviral Accepted core data of Core data – now as 1st wk April 2021 COVAX vector encoding the Spike protein AZ – non-Covax donation for COVAX. antigen of the SARS-CoV-2. Data for Covax sites Awaited April 2021 onwards EU Nodes expected in April 2021 onwards 3. AZD1222 MFDS KOREA Recombinant ChAdOx1 adenoviral Finalized 15 Feb 2021 SK BIO vector encoding the Spike protein antigen of the SARS-CoV-2. 4. Serum Institute of India Covishield (ChAdOx1_nCoV- DCGI Recombinant ChAdOx1 adenoviral Finalized 15 Feb 2021 19) vector encoding the Spike protein antigen of the SARS-CoV-2. 5. Ad26.COV2.S EMA Recombinant, replication- Core data (US +NL sites) Finalized 12 March 2021 incompetent adenovirus type 26 (Ad26) vectored vaccine encoding Additional sites awaited Awaited To be fixed after data the (SARS-CoV-2) Spike (S) protein submission 6. 1 SARS-CoV-2 Vaccine (Vero NMPA Inactivated, produced in Vero cells In progress End April 2021 Sinopharm / BIBP Cell), Inactivated (lnCoV) 7. SARS-CoV-2 Vaccine (Vero NMPA Inactivated, produced in Vero cells In progress End April 2021 Cell), Inactivated 8. mRNA-1273 EMA mNRA-based vaccine In progress using the Mid. April 2021 encapsulated in lipid nanoparticle abridged procedure (LNP) (EMA).
    [Show full text]
  • March 17, 2021
    1996 - 2021 SILVER JUBILEE YEAR TMQ to Marquez expand speeds up return operations ahead of Qatar in Qatar double-header Business | 01 Sport | 12 WEDNESDAY 17 MARCH 2021 4 SHA'ABAN - 1442 VOLUME 26 NUMBER 8564 www.thepeninsula.qa 2 RIYALS QFFD signs $10m contribution Amir visits Milipol Qatar 2021 agreement to support WHO QNA — DOHA that one billion more people benefiting from UHC, one The State of Qatar, repre- billion more people sup- sented by Qatar Fund for ported during emergencies Development (QFFD), and the and one billion more World Health Organization enjoying better health and (WHO) have signed a Core well-being. It also supports Contribution Agreement for the initiatives of speeding $10m to support WHO’s Thir- Core Contribution Agreement is up the access to the teenth General Programme of to support WHO’s Thirteenth essential supplies needed in Work (GPW 13) and for General Programme of Work the fight against COVID-19, COVID-19 response through (GPW 13) and for COVID-19 to include accelerating the the Access to COVID-19 Tools development of COVID-19 Accelerator (ACT-A). response through the Access to tests, treatment and vacci- This is the first Core Con- COVID-19 Tools Accelerator nation while ensuring fair tribution Agreement signed (ACT-A). access.” between the State of Qatar Dr. Hanan Al Kuwari com- and WHO, highlighting the The State of Qatar through mended the pivotal role of strong partnership and com- WHO, especially in the current mitment to work jointly Qatar Fund for Development difficult time as the world is ensuring the most vulnerable (QFFD) is providing its first fighting the coronavirus communities around the flexible funding to WHO in (COVID-19) pandemic.
    [Show full text]
  • “Estamos Trabajando Para La Nueva Normalidad”
    K Y M C EN FALLIDO ROBO Distribución en La Plata, Berisso y Ensenada. Precio de tapa: $50 Incendiaron un club a Entrega bajo puerta: $50 metros del destacamento policial de Arturo Seguí Año XXVII • Nº 8866 -PÁG. TRAMA URBANA Edición de 32 páginas En la noticia La Plata, lunes 28 de junio de 2021 15 Boom exportador bonaerense En lo que refiere a ventas al exterior, “Estamos trabajando para la Provincia tuvo este año su cuatrimestre récord en casi una década. El fenómeno es impulsado por el crecimiento de las Diario laHoy dialogó nueva con el presidente de la normalidad”Universidad Nacional de La Plata, Fernando Tauber, quien manufacturas, pero también por otras producciones que atraen a se refirió a la importante labor que desarrollan desde las diferentes áreas para enfrentar la pandemia países como Indonesia e Irán -PÁG. 10 -PÁG. 6 Descubren dos nuevos ejemplares de yaguareté -PÁG. 13 Rápidos y furiosos 9 lidera la taquilla -PÁG. 12 ESPECTÁCULOS FÚTBOL “AMERICANO” Juega la Selección y diario Hoy entrevistó a los campeones Con el fin de agasajar al personal sanitario y agradecerle por su esfuerzo en la pandemia, vecinos de Ringuelet El conjunto de Scaloni enfrentará desde desdeAmor hace tres meses regalan facturasy ensolidaridad las guardias de los nosocomios y en las postas de vacunación las 21 a Bolivia buscando asegurarse la cima del Grupo A. Este multimedio -PÁG. 9 conversó en Brasilia con los integrantes del equipo de fútbol americano que ganaron allí el segundo título consecutivo Los lugares ideales para el cicloturismo en Argentina -PÁG. 15 -PÁGS.
    [Show full text]
  • Olga Lidia Jacobo-Casanueva MS Director, Center for State Control of Medicines and Medical Devices (CECMED)
    Cuba's Women of Science Cuba’s National Regulatory Authority & COVID-19: Olga Lidia Jacobo-Casanueva MS Director, Center for State Control of Medicines and Medical Devices (CECMED) Tania L. Aguilar-Guerra MD MS, Esther M. Fajardo-Díaz MS, Conner Gorry MA As of this writing, more than 4.6 million Cubans (over 40% of the population on the island), had received at least their E. Añé fi rst dose of Soberana 02 or Abdala, two of fi ve vaccine candidates for SARS-CoV-2 developed and produced on the island. Late-phase clinical trial data revealed that Abdala is 92.28% effective after the full, three-dose cycle and Soberana 02 is 91.2% effective after two doses, when followed by a booster of Soberana Plus.[1] Cuban health authorities have committed to vaccinating the entire population, including children aged 3–18 years old, using these vaccines by the end of 2021. The fi rst pre-clinical, peer-reviewed data are available,[2] with clinical trial results already submitted to various international journals. Building on decades of biotechnology know-how developing, producing and administering 11 preventive vaccines for childhood diseases—used in the nation’s universal health system and also marketed elsewhere—Cuba is the fi rst, and to date only, country in Latin America and the Caribbean to develop its own vaccine candidates for COVID-19 (Soberana 01; Soberana 02; Soberana Plus; Abdala and Mambisa; see Box on following page). In a strategy designed to ensure comprehensive and importantly, independent solutions to the global health crisis, research institutes and manufacturing hands-on experience in nearly every facet of regulation.
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 19 Luglio 2021
    Coronavirus: quello che c’è da sapere – 19 luglio 2021 Sommario Quando è iniziata l’epidemia? ......................................2 Che cosa sono i test sierologici? a cosa servono? ................................26 Quando è arrivata in Italia? ..........................................2 Chi viene colpito dalla malattia Covid-19? ............................................26 A cosa è dovuta l’infezione? .........................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................26 Quanto è diffusa l’epidemia? ....................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....31 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Il virus può diventare endemico?............................................................32 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................33 Come si trasmette l’infezione? ...............................................................10 Quali sono le terapie disponibili?............................................................48 I bambini sono più soggetti all’infezione? .............................................14 Quali sono i rischi sanitari legati all’epidemia? .....................................60
    [Show full text]
  • Current Scenario of Sars-Coronavirus 2: Epidemiology; Post-Covid-19 and Global Impacts
    CURRENT SCENARIO OF SARS-CORONAVIRUS 2: EPIDEMIOLOGY; POST-COVID-19 AND GLOBAL IMPACTS Vishnu Priya Sampatha*, Prasannaraj Govindarajb, Ramasamy Subbiah c, Makesh Mohand Address(es): a State-Key Laboratory for Mechanical Behavior of Materials, School of Material Science & Engineering, Xi'an Jiaotong University, Xi'an 710049, China. b Neurochemistry Laboratory, Department of Neurological Sciences, Christian Medical College and Hospital, Vellore 632004, Tamil Nadu, India. c Cardiac Hypertrophy Laboratory, Department of Molecular Biology, School of Biological Sciences, Madurai Kamaraj University, Madurai 625021, Tamil Nadu, India. d Department of Physics, National Institute of Technology, Karnataka (NITK) Surathkal 575025, Karnataka, India. *Corresponding author: [email protected] https://doi.org/10.15414/jmbfs.4066 ARTICLE INFO ABSTRACT Received 11. 12. 2020 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a highly contagious strain of coronavirus that causes Coronavirus Disease 2019 (COVID-19) infection, which has distressed the world's health and wealth. This Global Pandemic outbreak has affected Revised 17. 6. 2021 public health enormously at various customs. The investigation of SARS-CoV-2 is still at infancy; however, based on the available Accepted 29. 6. 2021 reports, this review gives an overview of the epidemiology, genomic landscape, diversity of SARS-CoV-2, viral genome pathogenic Published xx.xx.201x interactions, associating factors for COVID-19 infections, post-COVID-19, disease manifestations with their comorbidities, the major obstacles and the preventive measures along with current vaccine strategies of SARS-CoV-2. This review also summarizes all the Regular article relevant evidence of COVID-19 illness, which can provide valuable information on the SARS-CoV-2 genome and its mode of action strategies, thus delivering additional knowledge about COVID-19.
    [Show full text]
  • INDIA the Government Must Revitalise Public Sector Units to Meet COVID-19 Vaccine Requirements
    16-30 APRIL, 2021 DownToEarthSCIENCEFORTNIGHTLY AND ENVIRONMENTON POLITICS OF FORTNIGHTLY DEVELOPMENT, ENVIRONMENT AND HEALTH Subscriber copy, not for resale `60.00 AFRICA Inequitable global distribution of vaccines will only prolong the pandemic for every country AT RISK AT INDIA The government must revitalise public sector units to meet COVID-19 vaccine requirements 01Cover.indd 1 12/04/21 9:41 AM Advertisement 02JSES- Magazine Advt- Feb 2021- PDF.indd 2 09/04/21 12:32 PM SUNITA NARAIN \EDIT Zero-zero, net zero E HAVE seen furious activity on climate change in the first weeks of April in Delhi. No, I am not talking about action to fight climate change. I am talking about words and more words—much has been W written about the position that India must take or not take when it comes to declaring a net-zero goal. Much has been discussed in closed-door meetings on the same. John Kerry, the US climate envoy, was in town in the lead up to President Joe Biden’s climate leaders summit on April 22-23. He wanted to cajole and push us to act—say something big when the leaders meet. The good news is that climate change is back on the agenda. The bad news is that we are discussing the wrong things; we are in danger of once again losing the opportunity to drive home the need for ambition and equity in climate change action. Just consider the narrative in Delhi. It was not about the need to take stock of what has been done or not done to meet the Paris commitments—the voluntary targets countries have taken to reduce greenhouse gas emissions in this decade; it was not about how minuscule, completely off track and inequitable the Paris targets are.
    [Show full text]